Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Empresa reivindicada
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions consulte Mais informação
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
Qual é a coisa mais positiva da cultura e do ambiente da sua empresa?
The excitement associated with the expanded use of XPOVIO.
O que faz você mais feliz no trabalho?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Other Employee Reviews for Karyopharm Therapeutics
×